178 related articles for article (PubMed ID: 21903859)
21. Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions.
Ushijima H; Suzuki Y; Oike T; Komachi M; Yoshimoto Y; Ando K; Okonogi N; Sato H; Noda SE; Saito J; Nakano T
J Radiat Res; 2015 Jul; 56(4):663-8. PubMed ID: 25887043
[TBL] [Abstract][Full Text] [Related]
22. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
Fung AS; Wu L; Tannock IF
Clin Cancer Res; 2009 Sep; 15(17):5389-95. PubMed ID: 19706800
[TBL] [Abstract][Full Text] [Related]
23. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
24. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Thelen P; Krahn L; Bremmer F; Strauss A; Brehm R; Loertzer H
Int J Mol Med; 2013 Feb; 31(2):339-46. PubMed ID: 23292124
[TBL] [Abstract][Full Text] [Related]
25. Curcumin enhances the response of non-Hodgkin's lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation.
Qiao Q; Jiang Y; Li G
Oncol Rep; 2013 Jan; 29(1):380-6. PubMed ID: 23117293
[TBL] [Abstract][Full Text] [Related]
26. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
27. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
[TBL] [Abstract][Full Text] [Related]
28. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.
Potiron VA; Abderrahmani R; Giang E; Chiavassa S; Di Tomaso E; Maira SM; Paris F; Supiot S
Radiother Oncol; 2013 Jan; 106(1):138-46. PubMed ID: 23321494
[TBL] [Abstract][Full Text] [Related]
29. The combination of temsirolimus and chloroquine increases radiosensitivity in colorectal cancer cells.
Shiratori H; Kawai K; Hata K; Tanaka T; Nishikawa T; Otani K; Sasaki K; Kaneko M; Murono K; Emoto S; Sonoda H; Nozawa H
Oncol Rep; 2019 Jul; 42(1):377-385. PubMed ID: 31059051
[TBL] [Abstract][Full Text] [Related]
30. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer.
Masiello D; Mohi MG; McKnight NC; Smith B; Neel BG; Balk SP; Bubley GJ
Cancer Biol Ther; 2007 Feb; 6(2):195-201. PubMed ID: 17218776
[TBL] [Abstract][Full Text] [Related]
31. A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.
McHugh DJ; Chudow J; DeNunzio M; Slovin SF; Danila DC; Morris MJ; Scher HI; Rathkopf DE
Clin Genitourin Cancer; 2020 Jun; 18(3):171-178.e2. PubMed ID: 32057715
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.
Wu Y; Chhipa RR; Cheng J; Zhang H; Mohler JL; Ip C
Anticancer Res; 2010 Oct; 30(10):3895-901. PubMed ID: 21036700
[TBL] [Abstract][Full Text] [Related]
34. The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
Kim SY; Jeong EH; Lee TG; Kim HR; Kim CH
Anticancer Res; 2021 Jun; 41(6):2885-2894. PubMed ID: 34083279
[TBL] [Abstract][Full Text] [Related]
35. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Cerniglia GJ; Karar J; Tyagi S; Christofidou-Solomidou M; Rengan R; Koumenis C; Maity A
Mol Pharmacol; 2012 Dec; 82(6):1230-40. PubMed ID: 22989521
[TBL] [Abstract][Full Text] [Related]
37. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.
Amato RJ; Wilding G; Bubley G; Loewy J; Haluska F; Gross ME
Clin Genitourin Cancer; 2012 Dec; 10(4):232-8. PubMed ID: 22695254
[TBL] [Abstract][Full Text] [Related]
38. Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.
Facompre ND; Sinha I; El-Bayoumy K; Pinto JT; Sinha R
Int J Cancer; 2012 Nov; 131(9):2134-42. PubMed ID: 22307455
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor.
Harashima K; Akimoto T; Nonaka T; Tsuzuki K; Mitsuhashi N; Nakano T
Int J Radiat Biol; 2005 Jan; 81(1):63-76. PubMed ID: 15962764
[TBL] [Abstract][Full Text] [Related]
40. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.
Collak FK; Yagiz K; Luthringer DJ; Erkaya B; Cinar B
J Biol Chem; 2012 Jul; 287(28):23698-709. PubMed ID: 22619175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
